Thomas E. Wagner
YOU?
Author Swipe
View article: Tumor Lysate Particle Only Vaccine (TLPO) vs. Tumor Lysate Particle-Loaded, Dendritic Cell Vaccine (TLPLDC) to Prevent Recurrence in Resected Stage III/IV Melanoma Patients: Results of a Phase I/IIa Trial
Tumor Lysate Particle Only Vaccine (TLPO) vs. Tumor Lysate Particle-Loaded, Dendritic Cell Vaccine (TLPLDC) to Prevent Recurrence in Resected Stage III/IV Melanoma Patients: Results of a Phase I/IIa Trial Open
Background: The autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine is produced from dendritic cells (DC) loaded ex vivo with autologous tumor lysate (TL). TLPLDC has been shown to decrease recurrence in resected Stag…
View article: Tumor lysate particle only vaccine (TLPO) vs. Tumor lysate particle-loaded, dendritic cell vaccine (TLPLDC) to prevent recurrence in resected stage III/IV melanoma patients: Results of a phase I/IIa trial
Tumor lysate particle only vaccine (TLPO) vs. Tumor lysate particle-loaded, dendritic cell vaccine (TLPLDC) to prevent recurrence in resected stage III/IV melanoma patients: Results of a phase I/IIa trial Open
In a randomized, double-blind Phase I/IIa trial, there were no differences in DFS or OS in resected Stage III/IV melanoma patients receiving adjuvant TLPO versus TLPLDC vaccines. Given manufacturing advantages, further efficacy testing of …
View article: PATJ inhibits histone deacetylase 7 to control tight junction formation and cell polarity
PATJ inhibits histone deacetylase 7 to control tight junction formation and cell polarity Open
The conserved multiple PDZ-domain containing protein PATJ stabilizes the Crumbs-Pals1 complex to regulate apical-basal polarity and tight junction formation in epithelial cells. However, the molecular mechanism of PATJ’s function in these …
View article: Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis Open
Background The tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine is made by ex vivo priming matured autologous dendritic cells (DCs) with yeast cell wall particles (YCWPs) loaded with autologous tumor lysate (TL). The tumor ly…
View article: A <i>SEC61A1</i> variant is associated with autosomal dominant polycystic liver disease
A <i>SEC61A1</i> variant is associated with autosomal dominant polycystic liver disease Open
Background and Aims Autosomal dominant polycystic liver and kidney disease is a spectrum of hereditary diseases, which display disturbed function of primary cilia leading to cyst formation. In autosomal dominant polycystic kidney disease a…
View article: 542 Randomized trial of tumor lysate particle only vaccine vs. tumor lysate particle-loaded, dendritic cell vaccine to prevent recurrence of resected stage III/IV melanoma: 36-month analysis
542 Randomized trial of tumor lysate particle only vaccine vs. tumor lysate particle-loaded, dendritic cell vaccine to prevent recurrence of resected stage III/IV melanoma: 36-month analysis Open
Background The tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine is an autologous tumor vaccine that decreased recurrence in stage III/IV melanoma when granulocyte-colony stimulating factor (G-CSF) was not used to harvest the …
View article: Multi‐institutional, prospective, randomized, double‐blind, placebo‐controlled phase IIb trial of the tumor lysate, particle‐loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high‐risk melanoma patients: A subgroup analysis
Multi‐institutional, prospective, randomized, double‐blind, placebo‐controlled phase IIb trial of the tumor lysate, particle‐loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high‐risk melanoma patients: A subgroup analysis Open
Background Checkpoint inhibitors (CPI) in combination with cell‐based vaccines may produce synergistic antitumor immunity. The primary analysis of the randomized and blinded phase IIb trial in resected stage III/IV melanoma demonstrated TL…
View article: Pals1 prevents Rac1-dependent colorectal cancer cell metastasis by inhibiting Arf6
Pals1 prevents Rac1-dependent colorectal cancer cell metastasis by inhibiting Arf6 Open
Loss of apical-basal polarity and downregulation of cell-cell contacts is a critical step during the pathogenesis of cancer. Both processes are regulated by the scaffolding protein Pals1, however, it is unclear whether the expression of Pa…
View article: Additional file 1 of Pals1 prevents Rac1-dependent colorectal cancer cell metastasis by inhibiting Arf6
Additional file 1 of Pals1 prevents Rac1-dependent colorectal cancer cell metastasis by inhibiting Arf6 Open
Additional file 1: Supplementary Fig. 1. Pals1-deficient HCT116 cells do not exhibit defects in cell-cell contacts but increased motility. a Western blot analysis of the expression level of Pals1 in HCT116 and CRISPR/Cas9 generated HCT116Δ…
View article: 300 Final analysis of a prospective, randomized, double-blind, placebo-controlled phase IIb trial of tumor lysate, particle-loaded, dendritic cell vaccine in stage III/IV melanoma: 36-month analysis
300 Final analysis of a prospective, randomized, double-blind, placebo-controlled phase IIb trial of tumor lysate, particle-loaded, dendritic cell vaccine in stage III/IV melanoma: 36-month analysis Open
Background The tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine is created ex vivo by loading autologous dendritic cells (DC) with yeast cell wall particles (YCWP) containing autologous tumor lysate, thus delivering tumor ant…
View article: 431 Prospective, randomized trial of the tumor lysate, particle only vaccine compared to the tumor lysate, particle-loaded, dendritic cell vaccine to prevent recurrence for resected stage III/IV melanoma
431 Prospective, randomized trial of the tumor lysate, particle only vaccine compared to the tumor lysate, particle-loaded, dendritic cell vaccine to prevent recurrence for resected stage III/IV melanoma Open
Background The autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine is safe and effective in improving 24 and 36-month disease-free survival (DFS) in patients (pts) with resected stage III/IV melanoma who completed the…
View article: 310 The effect of pretreatment with G-CSF prior to dendritic cell collection during the phase IIb trial of an autologous DC-based vaccine for advanced, resectable melanoma
310 The effect of pretreatment with G-CSF prior to dendritic cell collection during the phase IIb trial of an autologous DC-based vaccine for advanced, resectable melanoma Open
Background We have completed a prospective, randomized, multi-center, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle loaded, dendritic cell (TLPLDC) vaccine given to prevent recurrences in patients with rese…
View article: Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial
Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial Open
ClinicalTrials.gov, NEXUS; NCT02379091 , submitted November 28, 2014.
View article: "If The Situation Seemed Insurmountable, I Always Wanted To Be There": Virginia Coffey, A Midwest Human Relations Pioneer
"If The Situation Seemed Insurmountable, I Always Wanted To Be There": Virginia Coffey, A Midwest Human Relations Pioneer Open
The devastating 1943 rioting in Detroit led to the formation of municipal human relations committees across the country, and among the oldest of these was the Cincinnati Mayor’s Friendly Relations Committee. Five years after its founding, …
View article: Preclinical testing of a novel personalized cancer vaccine for all solid tumors and all patients
Preclinical testing of a novel personalized cancer vaccine for all solid tumors and all patients Open
Meeting abstracts A variety of autologous tumor/dendritic-cell (DC) vaccines have been pursued. Our prior autologous tumor/DC fusion (dendritoma) vaccine demonstrated clinical benefit in metastatic melanoma; however, dendritoma production …